tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

OPT Stock Latest News

Opthea completes 1 for 1.22 accelerated non-renounceable entitlement offer
The FlyOpthea completes 1 for 1.22 accelerated non-renounceable entitlement offer
1d ago
OPT
Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer
PremiumPress Releases
Opthea Announces Results of the A$55.9m (US$36.9m¹) Retail Entitlement Offer
2d ago
OPT
Opthea announces publication on VEGF-C, VEGF-D signaling pathways
PremiumThe Fly
Opthea announces publication on VEGF-C, VEGF-D signaling pathways
7d ago
OPT
Opthea’s Sozinibercept Shows Promise for Wet AMD
PremiumCompany Announcements
Opthea’s Sozinibercept Shows Promise for Wet AMD
7d ago
6K
OPT
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens
PremiumPress Releases
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens
28d ago
OPT
Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)
PremiumPress ReleasesOpthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)
1M ago
OPT
Opthea looks to raise $150M via an $6.6M placement, $143.4M ANREO
PremiumThe Fly
Opthea looks to raise $150M via an $6.6M placement, $143.4M ANREO
1M ago
OPT
Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)
PremiumPress Releases
Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)
1M ago
OPT
Opthea Ltd (ADR) trading halted, news pending
PremiumThe Fly
Opthea Ltd (ADR) trading halted, news pending
1M ago
OPT
Opthea To Present at Clinical Trials at the Summit Meeting
PremiumPress Releases
Opthea To Present at Clinical Trials at the Summit Meeting
1M ago
OPT
Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD
PremiumPress Releases
Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD
2M ago
OPT
Opthea completes enrollment in Phase 3 clinical program with sozinibercept
PremiumThe Fly
Opthea completes enrollment in Phase 3 clinical program with sozinibercept
2M ago
OPT
These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 400%, Says Oppenheimer
PremiumStock Analysis & IdeasThese 2 ‘Strong Buy’ Penny Stocks Could Surge Over 400%, Says Oppenheimer
2M ago
OPT
TARA
Opthea Announces Upcoming Presentations at the Retina World Congress 2024
PremiumPress Releases
Opthea Announces Upcoming Presentations at the Retina World Congress 2024
3M ago
OPT
Opthea to Present at the OIS Retina Innovation Summit at ARVO
PremiumPress Releases
Opthea to Present at the OIS Retina Innovation Summit at ARVO
3M ago
OPT
Opthea Appoints John Han, PharmD, as VP Medical Affairs
PremiumPress Releases
Opthea Appoints John Han, PharmD, as VP Medical Affairs
3M ago
OPT
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference 
PremiumPress Releases
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference 
3M ago
OPT
Opthea Appoints Sujal Shah to the Board of Directors
PremiumPress Releases
Opthea Appoints Sujal Shah to the Board of Directors
3M ago
OPT
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
PremiumPress Releases
Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024
4M ago
OPT
Opthea to Participate in the Leerink Partners Global Biopharma Conference
PremiumPress ReleasesOpthea to Participate in the Leerink Partners Global Biopharma Conference
4M ago
OPT
Opthea Reports Half-Year Financial Results and Business Updates
PremiumPress Releases
Opthea Reports Half-Year Financial Results and Business Updates
5M ago
OPT
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
PremiumPress Releases
Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor
5M ago
OPT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >